Meeting
2013 ASCO Annual Meeting
Effectiveness of bevacizumab added to gold standard chemotherapy in metastatic colorectal cancer (mCRC): Final results from the Itaca randomized clinical trial.
Authors
Alessandro Passardi
IRCCS Istitituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
Alessandro Passardi , Emanuela Scarpi , Luigi Cavanna , Annalisa Fontana , Bernadette Vertogen , Silvia Ruscelli , Emiliano Tamburini , Angela Ragazzini , Giovanni Luca Frassineti , Oriana Nanni , Dino Amadori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
2007-004539-44
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3517)
DOI
10.1200/jco.2013.31.15_suppl.3517
Abstract #
3517
Poster Bd #
9
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Heinz-Josef Lenz
Poster
2019 Gastrointestinal Cancers Symposium
ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev A. Wainberg
Poster
2018 ASCO Annual Meeting
ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.
First Author: Zev A. Wainberg
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz